BioHarvest Announces Sales of Flagship Product VINIA Now Exceed $50 Million USD
BioHarvest Sciences (NASDAQ: BHST) announced that sales of its flagship product VINIA, a red grape cell-based supplement, have exceeded $50 million USD in cumulative sales. The majority of these sales occurred since the US launch less than 4 years ago.
The company has achieved over 50,000 active U.S. users on recurring subscription packages, with VINIA receiving approximately 8,000 customer reviews and a verified rating of 4.8/5. Clinical trials have demonstrated VINIA's ability to improve blood flow and arterial dilation.
To support future growth, BioHarvest plans to expand its production capacity by 4x with a new 100-ton per year facility, expected to be operational in late 2026. The company has invested 15 years and over $100M in developing its patented Botanical Synthesis technology, which is now being used in their CDMO Services division for pharmaceutical and nutrition industry partners.
BioHarvest Sciences (NASDAQ: BHST) ha annunciato che le vendite del suo prodotto di punta VINIA, un supplemento a base di cellule d'uva rossa, hanno superato i 50 milioni di dollari USD in vendite cumulative. La maggior parte di queste vendite è avvenuta dal lancio negli Stati Uniti meno di 4 anni fa.
L'azienda ha raggiunto oltre 50.000 utenti attivi negli Stati Uniti con pacchetti di abbonamento ricorrenti, con VINIA che ha ricevuto circa 8.000 recensioni da parte dei clienti e una valutazione verificata di 4.8/5. Gli studi clinici hanno dimostrato la capacità di VINIA di migliorare il flusso sanguigno e la dilatazione arteriosa.
Per supportare la crescita futura, BioHarvest prevede di espandere la sua capacità produttiva di 4 volte con un nuovo impianto da 100 tonnellate all'anno, previsto per essere operativo entro la fine del 2026. L'azienda ha investito 15 anni e oltre 100 milioni di dollari nello sviluppo della sua tecnologia brevettata di Sintesi Botanica, che ora viene utilizzata nella loro divisione CDMO Services per partner dell'industria farmaceutica e nutrizionale.
BioHarvest Sciences (NASDAQ: BHST) anunció que las ventas de su producto insignia VINIA, un suplemento a base de células de uva roja, han superado los 50 millones de dólares USD en ventas acumuladas. La mayoría de estas ventas se realizaron desde el lanzamiento en EE. UU. hace menos de 4 años.
La compañía ha alcanzado más de 50,000 usuarios activos en EE. UU. con paquetes de suscripción recurrentes, y VINIA ha recibido aproximadamente 8,000 reseñas de clientes y una calificación verificada de 4.8/5. Los ensayos clínicos han demostrado la capacidad de VINIA para mejorar el flujo sanguíneo y la dilatación arterial.
Para apoyar el crecimiento futuro, BioHarvest planea expandir su capacidad de producción en 4 veces con una nueva instalación de 100 toneladas por año, que se espera que esté en funcionamiento a finales de 2026. La empresa ha invertido 15 años y más de 100 millones de dólares en el desarrollo de su tecnología patentada de Síntesis Botánica, que ahora se utiliza en su división de Servicios CDMO para socios de la industria farmacéutica y de nutrición.
BioHarvest Sciences (NASDAQ: BHST)는 자사 주력 제품 VINIA의 누적 판매액이 5천만 달러를 초과했다고 발표했습니다. 이 제품은 적포도 세포 기반 보충제입니다. 이러한 판매의 대부분은 미국 출시 이후 4년이 채 되지 않아 이루어졌습니다.
회사는 반복 구독 패키지를 통해 5만 명 이상의 미국 활성 사용자를 확보했으며, VINIA는 약 8,000개의 고객 리뷰와 4.8/5의 검증된 평가를 받았습니다. 임상 시험은 VINIA가 혈류 개선 및 동맥 확장을 지원하는 능력을 입증했습니다.
향후 성장을 지원하기 위해 BioHarvest는 2026년 말까지 운영될 예정인 연간 100톤 규모의 새로운 생산 시설을 통해 생산 능력을 4배 확장할 계획입니다. 이 회사는 15년 이상과 1억 달러 이상의 비용을 투자하여 특허받은 식물 합성 기술을 개발했으며, 현재 제약 및 영양 산업 파트너를 위한 CDMO 서비스 부서에서 사용되고 있습니다.
BioHarvest Sciences (NASDAQ: BHST) a annoncé que les ventes de son produit phare VINIA, un complément à base de cellules de raisin rouge, ont dépassé 50 millions de dollars USD en ventes cumulées. La majorité de ces ventes ont eu lieu depuis le lancement aux États-Unis il y a moins de 4 ans.
La société a atteint plus de 50 000 utilisateurs actifs aux États-Unis avec des forfaits d'abonnement récurrents, VINIA ayant reçu environ 8 000 avis de clients et une note vérifiée de 4,8/5. Des essais cliniques ont démontré la capacité de VINIA à améliorer le flux sanguin et la dilatation des artères.
Pour soutenir sa croissance future, BioHarvest prévoit d'augmenter sa capacité de production par 4 avec une nouvelle installation de 100 tonnes par an, qui devrait être opérationnelle fin 2026. L'entreprise a investi 15 ans et plus de 100 millions de dollars dans le développement de sa technologie de Synthèse Botanique brevetée, qui est maintenant utilisée dans leur division CDMO Services pour des partenaires de l'industrie pharmaceutique et nutritionnelle.
BioHarvest Sciences (NASDAQ: BHST) gab bekannt, dass die Verkaufszahlen seines Hauptprodukts VINIA, einem auf roten Traubenzellen basierenden Nahrungsergänzungsmittel, 50 Millionen USD an kumulierten Verkaufszahlen überschritten haben. Der Großteil dieser Verkäufe fand seit dem US-Launch vor weniger als 4 Jahren statt.
Das Unternehmen hat über 50.000 aktive Nutzer in den USA mit wiederkehrenden Abonnementpaketen erreicht, wobei VINIA etwa 8.000 Kundenbewertungen und eine verifizierte Bewertung von 4,8/5 erhalten hat. Klinische Studien haben die Fähigkeit von VINIA zur Verbesserung des Blutflusses und zur Arterienerweiterung nachgewiesen.
Um zukünftiges Wachstum zu unterstützen, plant BioHarvest, seine Produktionskapazität mit einer neuen Anlage für 100 Tonnen pro Jahr um das 4-fache zu erweitern, die voraussichtlich Ende 2026 in Betrieb genommen wird. Das Unternehmen hat 15 Jahre und über 100 Millionen USD in die Entwicklung seiner patentierten Botanischen Synthesetechnologie investiert, die nun in der CDMO-Services-Sparte für Partner der Pharma- und Ernährungsindustrie eingesetzt wird.
- Achieved $50M USD in cumulative VINIA sales
- Strong customer base with 50,000+ active U.S. subscribers
- High product rating of 4.8/5 from 8,000 customer reviews
- Planned 4x production capacity expansion with new facility
- Clinical trials validate product efficacy for heart health
- Significant investment of $100M and 15 years before reaching current sales levels
- New production facility won't be operational until late 2026
Insights
BioHarvest's announcement reveals several critical business developments that signal strong market validation and growth potential. The $50 million cumulative sales milestone for VINIA, achieved primarily in under 4 years in the US market, demonstrates successful product-market fit in the competitive nutraceutical space. More importantly, the 50,000 active subscribers represent a robust recurring revenue base that provides predictable cash flows and reduces customer acquisition costs.
The subscription model's success is particularly noteworthy, with a 4.8/5 verified rating from 8,000 reviews indicating strong product satisfaction and potential for high customer retention rates. This metric is important for subscription-based businesses, as it typically correlates with lower churn rates and higher lifetime customer value.
The planned 4x production capacity expansion through a new 100-ton facility represents a strategic scaling initiative. While this will require significant capital investment, it positions the company to meet growing demand and potentially reduce unit production costs through economies of scale. The 2026 operational timeline suggests confidence in sustained growth trajectory and market demand forecasts.
The company's CDMO Services division adds a compelling B2B revenue stream, diversifying from the direct-to-consumer model. Partnerships with pharmaceutical and nutrition companies could provide high-margin opportunities and validate the broader applicability of their Botanical Synthesis technology platform. The $100 million R&D investment in this proprietary technology has created significant intellectual property barriers, potentially providing sustainable competitive advantages in both consumer products and B2B services.
Commercial success of VINIA validates the power of BioHarvest's patented Botanical Synthesis technology to produce valuable plant-based Compounds at industrial scale
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - February 18, 2025) - BioHarvest Sciences Inc., (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today announced that its Red Grape Cell composition - known commercially as VINIA® - has now exceeded
VINIA®, a red grape cell-based supplement, is produced by BioHarvest's proprietary Botanical Synthesis platform technology. VINIA® was launched in the United States as a direct-to-consumer product in May 2021, and as of February 16th 2025, has also achieved a major milestone of over 50,000 active U.S. users on recurring subscription packages.
BioHarvest has conducted a number of clinical trials on VINIA® to support its heart-health claims, which includes a clinical trial that demonstrated VINIA's ability to significantly increase dilation of arteries and improve overall blood flow. In the USA, VINIA® has received approximately 8,000 customer reviews with a verified rating of 4.8/5*. The growing active subscription base and positive customer reviews are a testimonial of the efficacy of the product and its growth potential both in the U.S. and globally.
As a reflection of the Company's confidence in the trajectory of the business, BioHarvest plans to support future growth by expanding its production capacity by 4x with the building of a new 100 ton per year production facility, expected to be operational in late 2026.
"We spent 15 years and over
"In addition to the compounds within our Products division pipeline, our growing CDMO Services division now has multiple compounds being developed under contract with Pharmaceutical and Nutrition industry partners. I am confident that we have the plan and the team in place to achieve our vision of developing life-changing compounds from plants that improve the health and wellness of millions of people, whilst preserving the planet for generations to come," concluded Sobel.
About Botanical Synthesis
Botanical synthesis is a non-GMO technology that replicates and improves nature's process at scale - it delivers new patentable compounds by growing plant cells which can mirror and magnify the phyto-nutrients contained in specific targeted plants, delivering all the benefits of the plant without having to grow the plant itself.
About VINIA®
VINIA® is the first commercial nutraceutical product derived from the Botanical Synthesis platform and is clinically proven to improve blood flow, which enhances physical energy and mental alertness. VINIA® contains multiple polyphenols, including Piceid Resveratrol, which is 25x more soluble in water than regular resveratrol. VINIA® significantly dilates arteries by increasing Nitric Oxide levels in the blood (which act as a vasodilator) and by reducing the Endothelin-1 levels in the blood (which act as a vasoconstrictor). VINIA® currently has over 8,000 verified online reviews and an average 4.8/5* consumer rating. To learn more, please visit www.vinia.com.
*BioHarvest encourages all customers to leave honest and uncensored feedback. Customers receive a 30-day supply when they submit a review, whether positive or negative.
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based molecules, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. "Forward-Looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." In particular, there is no assurance the company will expand its capacity 4 times or complete construction of a 100 ton facility by late 2026 or at all. Achieving this objective is subject to inherent risks and delays including without limitation, construction delays, delays in delivery of components, labor disruptions and financing risks and uncertainties. There is no assurance that the company will be successful in developing new compounds that will improve the health of large numbers of people. Development of such products is subject to risks that they may not adapt to the company's process, to withdrawal of partner support, and any such products developed will be subject to market acceptance risks.
Readers are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and any other risks identified in other filings made by the Company with the Securities and Exchange Commission.
This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibilities for its contents.
BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations & Director
+1 (604) 622-1186
info@bioharvest.com
Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
+1 (949) 259-4987
BHSC@mzgroup.us
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/241264
FAQ
How much has BHST's VINIA product generated in total sales?
What is the current number of active VINIA subscribers for BHST?
When will BHST's new production facility be operational?
What is the customer satisfaction rating for BHST's VINIA product?
How much has BHST invested in developing its Botanical Synthesis technology?
